Personalized medicine in colorectal cancer: a comprehensive study of precision diagnosis and treatment.

Personalized medicine Pub Date : 2025-02-01 Epub Date: 2025-02-09 DOI:10.1080/17410541.2025.2459050
Fatemeh Gila, Somayeh Khoddam, Zahra Jamali, Mohmmad Ghasemian, Shayan Shakeri, Zeinab Dehghan, Jafar Fallahi
{"title":"Personalized medicine in colorectal cancer: a comprehensive study of precision diagnosis and treatment.","authors":"Fatemeh Gila, Somayeh Khoddam, Zahra Jamali, Mohmmad Ghasemian, Shayan Shakeri, Zeinab Dehghan, Jafar Fallahi","doi":"10.1080/17410541.2025.2459050","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer is a common and fatal disease that affects many people globally. CRC is classified as the third most prevalent cancer among males and the second most frequent cancer among females worldwide. The purpose of this article is to examine how personalized medicine might be used to treat colorectal cancer. The classification of colorectal cancer based on molecular profiling, including the detection of significant gene mutations, genomic instability, and gene dysregulation, is the main topic of this discussion. Advanced technologies and biomarkers are among the detection methods that are explored, demonstrating their potential for early diagnosis and precise prognosis. In addition, the essay explores the world of treatment possibilities by providing light on FDA-approved personalized medicine solutions that provide individualized and precise interventions based on patient characteristics. This article assesses targeted treatments like cetuximab and nivolumab, looks at the therapeutic usefulness of biomarkers like microsatellite instability (MSI) and circulating tumor DNA (ctDNA), and investigates new approaches to combat resistance. Through this, our review provides a thorough overview of personalized medicine in the context of colorectal cancer, ultimately highlighting its potential to revolutionize the field and improve patient care.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"59-81"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17410541.2025.2459050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer is a common and fatal disease that affects many people globally. CRC is classified as the third most prevalent cancer among males and the second most frequent cancer among females worldwide. The purpose of this article is to examine how personalized medicine might be used to treat colorectal cancer. The classification of colorectal cancer based on molecular profiling, including the detection of significant gene mutations, genomic instability, and gene dysregulation, is the main topic of this discussion. Advanced technologies and biomarkers are among the detection methods that are explored, demonstrating their potential for early diagnosis and precise prognosis. In addition, the essay explores the world of treatment possibilities by providing light on FDA-approved personalized medicine solutions that provide individualized and precise interventions based on patient characteristics. This article assesses targeted treatments like cetuximab and nivolumab, looks at the therapeutic usefulness of biomarkers like microsatellite instability (MSI) and circulating tumor DNA (ctDNA), and investigates new approaches to combat resistance. Through this, our review provides a thorough overview of personalized medicine in the context of colorectal cancer, ultimately highlighting its potential to revolutionize the field and improve patient care.

结直肠癌个体化医疗:精准诊断与治疗的综合研究。
结直肠癌是一种常见的致命疾病,影响着全球许多人。在全球范围内,结直肠癌被列为男性中第三常见的癌症,女性中第二常见的癌症。本文的目的是研究如何使用个性化药物治疗结直肠癌。基于分子谱的结直肠癌分类,包括检测显著的基因突变、基因组不稳定和基因失调,是本讨论的主要主题。先进的技术和生物标志物是正在探索的检测方法之一,展示了它们在早期诊断和精确预后方面的潜力。此外,本文通过提供fda批准的个性化医疗解决方案,根据患者特征提供个性化和精确的干预措施,探索了治疗可能性的世界。本文评估了西妥昔单抗和纳武单抗等靶向治疗,研究了微卫星不稳定性(MSI)和循环肿瘤DNA (ctDNA)等生物标志物的治疗作用,并研究了对抗耐药性的新方法。通过这一点,我们的综述提供了个体化治疗在结直肠癌背景下的全面概述,最终强调了其革命性的领域和改善患者护理的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信